Lung cancer: analysis of biomarkers and methods of diagnostic and prognostic value

Abstract

This paper summarizes the overwhelming evidence that targeted therapy is better than chemotherapy for the treatment of lung cancer. The focus is on lung cancer because of the sheer magnitude of this disease especially in males. In India, lung cancer constitutes 6.9 per cent of all new cancer cases and 9.3 per cent of all cancer related deaths in both sexes (1). Currently the world we reside has a norm of developing cure to an abnormal state of living body (so called disease) based on evidences, recognized during the diagnosis of the disease. It is done to ensure optimized therapy of treatment and maximize the outcome. Personalized medicine is also an uprising norm. In this kind, all the variables such as host, environment, patient, etc. are considered for an individual case and the course of treatment is followed based on the standard options available. Its main objective is the best interest of the patient. Through a survey conducted in the northern belt of the country we tried to determine the biomarkers currently being used and the scope of targeted therapy. Thus, in its most basic form medicine is not only a science but is also an art.

<p>Long-Noncoding RNA CASC9 Promotes Progression of Non-Small Cell Lung Cancer by Promoting the Expression of CDC6 Through Binding to HuR</p>

“…As novel therapeutic targets, lncRNAs have been studied a lot and their roles of modulation in lung cancers have been found in previous studies. 18,19 In the present study, lncRNA CASC9 was notably up-regulated in NSCLC tissues, indicating CASC9 might have a significant contribution to malignant behaviors of NSCLC. To verify this hypothesis, CASC9 was down-regulated via sh-CASC9 in A549 and SPC-A1 cells, and the cell proliferation and migration were observed to be attenuated obviously.…”

Effect of AGEs-RAGE system on the efficacy of PD-1 inhibitors in the treatment of driver-gene mutation negative advanced non-squamous non-small cell lung cancer

“…At present, immunotherapy, anti-angiogenesis, gene targeted therapy, radiotherapy and chemotherapy are the most commonly used treatments for nsNSCLC, and with the continuous development of precision medicine, the treatment of NSCLC has become more detailed and refined (16). For patients with driver gene mutation negative advanced nsNSCLC, the treatment is mostly based on chemotherapy drugs, combined with immunotherapy and anti-angiogenesis targeted drugs; however, long-term chemotherapy will seriously damage the immune function of patients and lead to a poor prognosis, so how to improve the curative effect and prolong patient survival has become one of the research hotspots (17,18).…”